\u201cNew TAVR Research Explores Adverse Outcomes, Disease Progression in Patients with Asymptomatic Severe AS\u201d<\/p>\n
Source: At ACC.25, the annual conference of the American College of Cardiology, researchers presented two key follow-up studies focused on data from the EARLY TAVR trial.<\/p>\n
Summary:
\n1. Background: The EARLY TAVR Trial
\n\u2022 A randomized controlled trial (RCT) comparing early transcatheter aortic valve replacement (TAVR) vs. clinical surveillance (CS) in 901 patients with asymptomatic severe aortic stenosis (AS).
\n\u2022 Mean age: 75.8 years, 69% male, STS risk score: 1.8% (low surgical risk).
\n\u2022 Primary outcome: Composite of all-cause mortality, stroke, and unplanned cardiovascular hospitalizations.
\n\u2022 Key finding: TAVR patients had a lower event rate (26.8%) compared to CS patients (45.3%), mainly due to fewer unplanned hospitalizations (20.9% vs. 41.7%).<\/p>\n
2. ACC.25 Follow-Up Analysis: Delayed vs. Early TAVR
\n\u2022 Study Aim: Evaluate outcomes of patients initially managed with CS who later developed symptoms and underwent delayed aortic valve replacement (AVR).
\n\u2022 Comparison groups:
\n\u2022 Early TAVR (n=444) vs. Delayed AVR (n=388).
\n\u2022 Findings:
\n\u2022 Delayed AVR had worse outcomes:
\n\u2022 Higher composite event rate (10.6% vs. 6.8%).
\n\u2022 Increased stroke risk (1.8% vs. 0.9% peri-procedural; 4.5% vs. 2.7% at 2 years).
\n\u2022 Higher all-cause mortality and heart failure hospitalizations.
\n\u2022 Acute valve syndrome (NYHA III\/IV, arrhythmias, LV dysfunction) was a major risk factor for adverse outcomes in delayed AVR patients.
\n\u2022 Conclusion: Early TAVR may prevent progression to acute valve syndrome and poor outcomes.<\/p>\n
3. Expert Opinions & Stroke Risk Considerations
\n\u2022 Dr. Robert Bonow (JAMA Cardiology Editor-in-Chief):
\n\u2022 Emphasized inevitability of TAVR in asymptomatic severe AS.
\n\u2022 Warned against waiting, as delaying intervention may increase stroke risk.
\n\u2022 Dr. Philippe G\u00e9n\u00e9reux (Lead Investigator):
\n\u2022 Expressed surprise at high stroke rates in delayed AVR.
\n\u2022 Hypothesized that severe AS itself may be a stroke risk factor.<\/p>\n
4. Biomarker Analysis for Risk Prediction
\n\u2022 NT-proBNP & hs-cTnT were measured to determine if they predict TAVR timing needs.
\n\u2022 Findings:
\n\u2022 Higher biomarker levels were linked to worse outcomes.
\n\u2022 However, they did not provide useful guidance for timing TAVR.
\n\u2022 Conclusion: AS progression is unpredictable, reinforcing the benefits of early TAVR regardless of biomarker levels.<\/p>\n
5. Industry Perspective
\n\u2022 Edwards Lifesciences (Study Sponsor):
\n\u2022 Reaffirmed commitment to advancing TAVR science and expanding Sapien valve use.
\n\u2022 Sapien valve has treated over 1 million patients worldwide.<\/p>\n
6. Final Takeaway
\n\u2022 Early TAVR appears to provide significant benefits over clinical surveillance, reducing hospitalizations, stroke, and mortality.
\n\u2022 Waiting for symptoms may increase risk of acute valve syndrome and poorer outcomes.
\n\u2022 The optimal timing for TAVR in asymptomatic AS patients remains a key research focus.<\/p>\n","protected":false},"excerpt":{"rendered":"
\u201cNew TAVR Research Explores Adverse Outcomes, Disease Progression in Patients with Asymptomatic Severe AS\u201d Source: At ACC.25, the annual conference of the American College of Cardiology, researchers presented two key follow-up studies focused on data from the EARLY TAVR trial. Summary: 1. Background: The EARLY TAVR Trial \u2022 A randomized controlled trial (RCT) comparing early […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6261","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6261"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6261\/revisions"}],"predecessor-version":[{"id":6262,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6261\/revisions\/6262"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}